Ambrx Biopharma
United States
acquired
acquired
Stage
About
Ambrx Biopharma is a clinical-stage biopharmaceutical company that uses an expanded genetic code platform to discover and develop antibody–drug conjugates (ADCs) and other engineered protein therapies for oncology and immune modulation. The company advanced clinical programs including ARX517 (PSMA-targeting) and ARX788 (HER2-targeting) and was acquired by Johnson & Johnson in March 2024.
Explore Ambrx Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.